1. Scrip
  2. >>Business

Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease

Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform

 
• By Sten Stovall

Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.

Inflammation_Stethoscope
The STING agonist program aims to kick-start innate immune responses in tumors • Source: Shutterstock

German drug maker Bayer AG has entered a research and licensing agreement with privately held Curadev Pharma Pvt. Ltd. of India to explore and develop so-called stimulation of interferon genes (STING) antagonists across a number of inflammatory diseases, beginning initially in lung and heart conditions.

Curadev is a small molecule drug discovery biotech whose small molecule STING antagonist program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which...

More from Business

More from Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.